The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Open accessAbstract
BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study. METHODS: We randomly assigned 161 patients who had active rheumatoid arthritis despite treatment with methotrexate to receive one of four treatments: oral methotrexate (> or =10 mg per week) (control); rituximab (1000 mg on days 1 and 15); rituximab plus cyclophosphamide (750 mg on days 3 and 17); or rituximab plus methotrexate. Responses defined according to the criteria of the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) were assessed at week 24 (primary analyses) and week 48 (exploratory analyses). RESULTS: At week 24, the proportion of patients with 50 percent improvement in disease symptoms according to the ACR criteria, the primary end point, was significantly greater with the rituximab-methotrexate combination (43 percent, P=0.005) and the rituximab-cyclophosphamide combination (41 percent, P=0.005) than with methotrexate alone (13 percent). In all groups treated with rituximab, a significantly higher proportion of patients had a 20 percent improvement in disease symptoms according to the ACR criteria (65 to 76 percent vs. 38 percent, P< or =0.025) or had EULAR responses (83 to 85 percent vs. 50 percent, P< or =0.004). All ACR responses were maintained at week 48 in the rituximab-methotrexate group. The majority of adverse events occurred with the first rituximab infusion: at 24 weeks, serious infections occurred in one patient (2.5 percent) in the control group and in four patients (3.3 percent) in the rituximab groups. Peripheral-blood immunoglobulin concentrations remained within normal ranges. CONCLUSIONS: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotrexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, a reversible depletion of normal B cells is a well-tolerated side effect of the anti-CD20 antibody rituximab, which is an efficacious therapy in mature B cell neoplasms and in autoimmune disease”
From The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer (2015) · cites this paper as Edwards et al., 2004
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Hof, M. A. V., Kuper, H. H., Leeuwen, M. A. V., van de Putte, L. B. A., & van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,250
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,248
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B. J., Fürst, D. E., Goldsmith, C. H., Kieszak, S. M., Lightfoot, R. W., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,639
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A. B., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J., & Cambridge, G. (2001) · Lara D. Veeken · doi:10.1093/rheumatology/40.2.205 · Cited by 525
Self-citationClinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion
Leandro, M. J., Edwards, J. C. W., & Cambridge, G. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.10.883 · Cited by 344
Self-citationvan Gestel, A. M., Anderson, J. J., van Riel, P. L. C. M., Boers, M., HAAGSMA, C. J., Rich, B., Wells, G. A., Lange, M., & Felson, D. T. (1999) · PubMed · Cited by 250
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, E., Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Flagged first, then by citations
Research works printed but not linked: 3
- Van Gestel AM, 1999, J Rheumatol, 26, 705
- Tighe H, Carson DA. Rheumatoid factors. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB, eds. Textbook of rheumatology. 5th ed. Vol. 1. Philadelphia: W.B. Saunders, 1997:241-9.
- McLaughlin P, 1999, Semin Oncol, 26, 79
Cited by
Sorted by citations
Items 501–600 of 1,000
Komatsu, N., & Takayanagi, H. (2012) · Advances in immunology · doi:10.1016/b978-0-12-394299-9.00002-3 · Cited by 93
Rheumatic Disease in the Elderly: Rheumatoid Arthritis
Tutuncu, Z. N., & Kavanaugh, A. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.12.006 · Cited by 86
Gelinck, L. B. S., Teng, Y. K. O., Rimmelzwaan, G. F., van den Bemt, B. J. F., Kroon, F. P., & van Laar, J. M. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071878 · Cited by 87
Ferraro, A., Drayson, M. T., Savage, C. O. S., & MacLennan, I. C. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200737557 · Cited by 87
Dervieux, T., Zablocki, R., & Kremer, J. M. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq216 · Cited by 87
Molecular therapeutic targets in rheumatoid arthritis
Sacre, S. M., Andreakos, E., Taylor, P. C., Feldmann, M., & Foxwell, B. M. J. (2005) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399405009488 · Cited by 88
The role of collagen antibodies in mediating arthritis
Rowley, M. J., Nandakumar, K. S., & Holmdahl, R. (2008) · Modern Rheumatology · doi:10.1007/s10165-008-0080-x · Cited by 87
Kasperkiewicz, M., Shimanovich, I., Meier, M., Schumacher, N., Westermann, L., Kramer, J., Zillikens, D., & Schmidt, E. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10585.x · Cited by 86
Schmidt, E., Benoit, S., Bröcker, E., Zillikens, D., & Goebeler, M. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.2.147 · Cited by 86
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients
Genovese, M. C., Breedveld, F. C., Emery, P., Cohen, S. B., Keystone, E., Matteson, E. L., Baptiste, Y. J., Chai, A., Burke, L. S., Reiss, W. G., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.101675 · Cited by 86
Self-citationMonoclonal antibodies: technologies for early discovery and engineering
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1357002 · Cited by 89
Soliman, M. M., Hyrich, K. L., Lunt, M., Watson, K. D., Symmons, D. P. M., Ashcroft, D. M., & on behalf of the British Society for Rheumatology Biologics Register (2012) · Arthritis Care & Research · doi:10.1002/acr.21663 · Cited by 85
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
Marcinnò, A., Marnetto, F., Valentino, P., Martire, S., Balbo, A., Drago, A., Leto, M., Capobianco, M. A. N., Panzica, G., & Bertolotto, A. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000498 · Cited by 86
Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
Kridin, K., & Ahmed, A. R. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102466 · Cited by 89
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
Müller, F., Hagen, M., Wirsching, A., Kharboutli, S., Aigner, M., Völkl, S., Kretschmann, S., Tascilar, K., Taubmann, J., Bucci, L., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04185-6 · Cited by 102
Association of HLA–C3 and smoking with vasculitis in patients with rheumatoid arthritis
Turesson, C., Schaid, D. J., Weyand, C. M., Jacobsson, L., Goronzy, J. J., Petersson, I. F., Dechant, S. A., Nyhäll-Wåhlin, B.-M., Truedsson, L., Sturfelt, G. K., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22057 · Cited by 85
Hamel, K. M., Doodes, P. D., Cao, Y., Wang, Y., Martinson, J., Dunn, R., Kehry, M. R., Farkas, B., & Finnegan, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4994 · Cited by 85
Lovric, S., Erdbrüegger, U., Kumpers, P., Woywodt, A., Koenecke, C., Wedemeyer, H. H., Haller, H. G., & Haubitz, M. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn430 · Cited by 85
Reduced Fas ligand-expressing splenic CD5+B lymphocytes in severe collagen-induced arthritis
Lundy, S. K., & Fox, D. A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2795 · Cited by 85
Prospects for B-cell-targeted therapy in autoimmune disease
Edwards, J., & Cambridge, G. (2004) · Lara D. Veeken · doi:10.1093/rheumatology/keh446 · Cited by 85
Self-citationRituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders
Schmidt, E., Bröcker, E., & Goebeler, M. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8021-6 · Cited by 84
The safety of biologic therapies in RA-associated interstitial lung disease
Jani, M., Hirani, N., Matteson, E. L., & Dixon, W. G. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.197 · Cited by 86
The interplay between innate and adaptive immunity regulates cancer development
de Visser, K. E., & Coussens, L. M. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0702-5 · Cited by 83
Tsantikos, E., Oracki, S. A., Quilici, C., Anderson, G. P., Tarlinton, D. M., & Hibbs, M. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901878 · Cited by 83
Emerging role of immune cells as drivers of pulmonary fibrosis
Mutsaers, S. E., Miles, T., Prêle, C. M., & Hoyne, G. F. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108562 · Cited by 89
Du, J., Yang, H., Guo, Y., & Ding, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.009 · Cited by 83
Cortazar, F. B., Pendergraft, W. F., Wenger, J., Owens, C. T., Laliberte, K. A., & Niles, J. L. (2016) · Arthritis & Rheumatology · doi:10.1002/art.40032 · Cited by 83
Antibody repertoire analysis in polygenic autoimmune diseases
Bashford-Rogers, R. J. M., Smith, K. G. C., & Thomas, D. (2018) · Immunology · doi:10.1111/imm.12927 · Cited by 86
Konen, F. F., Möhn, N., Witte, T., Schefzyk, M., Wiestler, M., Lovric, S., Hufendiek, K., Schwenkenbecher, P., Sühs, K., Friese, M. A., et al. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103312 · Cited by 87
Long-term stability of diluted solutions of the monoclonal antibody rituximab
Paul, M., Vieillard, V., Jaccoulet, E., & Astier, A. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.06.063 · Cited by 82
Lee, Y. H., Bae, S., & Song, G. G. (2010) · Rheumatology International · doi:10.1007/s00296-010-1526-y · Cited by 82
B-Cell-Directed Therapy for Inflammatory Skin Diseases
Nagel, A. K., Hertl, M., & Eming, R. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.192 · Cited by 82
Galarza-Maldonado, C. M., Valencia, D., Tobón, G. J., Zurita, L., Mantilla, R. D., Pineda-Tamayo, R. A., Rojas‐Villarraga, A., Rueda, J. C., & Anaya, J. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8028-z · Cited by 82
Singh, J. A., Hossain, A., Tanjong-Ghogomu, E., Mudano, A., Maxwell, L. J., Buchbinder, R., Lopez-Olivo, M., Suarez-Almazor, M., Tugwell, P., & Wells, G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012591 · Cited by 65
A review on ethnobotany, phytochemistry and pharmacology of plant genus C aralluma R. Br
Adnan, M., Jan, S., Mussarat, S., Tariq, A., Begum, S., Afroz, A., & Shinwari, Z. K. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12265 · Cited by 86
Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab
Svoboda, J., Kotloff, R. M., & Tsai, D. E. (2006) · Transplant International · doi:10.1111/j.1432-2277.2006.00284.x · Cited by 81
Ma, L., Liu, B., Jiang, Z., & Jiang, Y. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2359-3 · Cited by 84
Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
Emery, P., Rigby, W. F. C., Tak, P. P., Dörner, T., Olech, E., Martín, C., Millar, L., Travers, H., & Fisheleva, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087379 · Cited by 81
Self-citationWright, C., Sibani, S., Trudgian, D. C., Fischer, R., Kessler, B. M., LaBaer, J., & Bowness, P. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m9.00384 · Cited by 81
Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab
McGonagle, D., Tan, A. L., Madden, J. M., Rawstron, A. C., Rehman, A., Emery, P., & Thomas, S. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem357 · Cited by 81
Self-citationB cells in rheumatoid arthritis
Bugatti, S., Codullo, V., Caporali, R. F., & Montecucco, C. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.017 · Cited by 81
The role of chemokines in rheumatoid arthritis and osteoarthritis
Vergunst, C. E., van de Sande, M. G. H., Lebre, M. C., & Tak, P. P. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740500439159 · Cited by 80
Quercetin-mediated SIRT1 activation attenuates collagen-induced mice arthritis
Shen, P., Lin, W., Ba, X., Huang, Y., Chen, Z., Han, L., Qin, K., Huang, Y., & Tu, S. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114213 · Cited by 80
Treatment of relapsing polychondritis with rituximab: A retrospective study of nine patients
Leroux, G., Costedoat-Chalumeau, N., Brihaye, B., Cohen‐Bittan, J., Amoura, Z., Haroche, J., Limal, N., Blétry, O., & Pietté, J. C. (2009) · Arthritis Care & Research · doi:10.1002/art.24366 · Cited by 80
CD20: A target antigen for immunotherapy of autoimmune diseases
Perosa, F., Favoino, E., Caragnano, M. A., Prete, M., & Dammacco, F. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.04.004 · Cited by 80
Hartgring, S. A. Y., van Roon, J. A. G., Wijk, M. W.-V., van der Wurff‐Jacobs, K. M. G., Jahangier, Z. N., Willis, C. R., Bijlsma, J. W. J., & Lafeber, F. P. J. G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24754 · Cited by 80
CD19 regulates the development of bleomycin‐induced pulmonary fibrosis in a mouse model
Komura, K., Yanaba, K., Horikawa, M., Ogawa, F., Fujimoto, M., Tedder, T. F., & Sato, S. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23995 · Cited by 86
Sardjono, C. T., Mottram, P. L., van de Velde, N. C., Powell, M. S., Power, D. A., Slocombe, R. F., Wicks, I. P., Campbell, I. K., McKenzie, S. E., Brooks, M., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21344 · Cited by 80
Pablos, J. L., Santiago, B., Tsay, D., Singer, M. S., Palao, G., Galindo-Izquierdo, M., & Rosen, S. D. (2005) · BMC Immunology · doi:10.1186/1471-2172-6-6 · Cited by 80
Modulation of Dendritic Cell Maturation and Function by B Lymphocytes
Bayry, J., Lacroix‐Desmazes, S., Kazatchkine, M. D., Hermine, O., Tough, D. F., & Kaveri, S. V. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.1.15 · Cited by 80
Soliman, M. M., Hyrich, K. L., Lunt, M., Watson, K. D., Symmons, D. P. M., Ashcroft, D. M., & the British Society for Rheumatology Biologics Register (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.110610 · Cited by 80
B Cells and Immunological Tolerance
Manjarrez‐Orduño, N., Quách, T. D., & Sanz, I. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.240 · Cited by 80
Rituximab in Autoimmune Hematologic Diseases: Not Just a Matter of B Cells
Stasi, R. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.010 · Cited by 79
Hepatitis B virus reactivation with a rituximab-containing regimen
Tsutsumi, Y. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i21.2344 · Cited by 79
Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects
Smolen, J. S., Redlich, K., Zwerina, J., Aletaha, D., Steiner, G. E., & Schett, G. A. (2005) · Clinical Reviews in Allergy & Immunology · doi:10.1385/criai:28:3:239 · Cited by 77
Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis: As Good as it Gets?
Szekanecz, Z., Soós, L., Szabó, Z., Fekete, A., Kapitány, A., Végvári, A., Sipka, S., Szűcs, G., Szántó, S., & Lakos, G. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8022-5 · Cited by 79
Roberts, D. M., Jones, R. B., Smith, R., Alberici, F., Kumararatne, D. S., Burns, S., & Jayne, D. R. W. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.11.004 · Cited by 79
Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome
Kaushik, V. V., Reddy, H. V., & Bucknall, R. C. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.047308 · Cited by 79
Higashida, J., Wun, T., Schmidt, S., Naguwa, S. M., & Tuscano, J. M. (2005) · PubMed · Cited by 79
B Cells, Be Gone — B-Cell Depletion in the Treatment of Rheumatoid Arthritis
Tsokos, G. C. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048114 · Cited by 79
Schmidt, E., Herzog, S., Brocker, E.-B., Zillikens, D., & Goebeler, M. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06740.x · Cited by 79
Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ
Nagashima, K., Sasseville, V. G., Wen, D., Bielecki, A., Yang, H., Simpson, C., Grant, E. P., Hepperle, M. E., Harriman, G., Jaffee, B., et al. (2006) · Blood · doi:10.1182/blood-2005-09-3852 · Cited by 80
Xavier Mariette, A., Rouanet, S., Sibilia, J., Combe, B. G., Loët, X. L., Tebib, J. G., Jourdan, R., & Dougados, M. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203480 · Cited by 78
Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE
Dörner, T., & Lipsky, P. E. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.158 · Cited by 80
Space Radiation Protection Countermeasures in Microgravity and Planetary Exploration
Montesinos, C. A., Khalid, R., Cristea, O., Greenberger, J. S., Epperly, M. W., Lemon, J. A., Boreham, D. R., Popov, D., Gorthi, G., Ramkumar, N., et al. (2021) · Life · doi:10.3390/life11080829 · Cited by 79
Low‐ Versus High‐Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta‐Analysis
Bredemeier, M., de Oliveira, F. K., & Rocha, C. M. (2013) · Arthritis Care & Research · doi:10.1002/acr.22116 · Cited by 78
Immunopathologic role of B lymphocytes in rheumatoid arthritis: Rationale of B cell-directed therapy
Martinez‐Gamboa, L., Brezinschek, H. P., Burmester, G. R., & Dörner, T. (2006) · Autoimmunity Reviews · doi:10.1016/j.autrev.2006.02.004 · Cited by 78
Biological Treatments in Behçet’s Disease: Beyond Anti-TNF Therapy
Caso, F., Costa, L., Rigante, D., Lucherini, O. M., Caso, P., Bascherini, V., Frediani, B., Cimaz, R., Marrani, E., Nieves-Martín, L., et al. (2014) · Mediators of Inflammation · doi:10.1155/2014/107421 · Cited by 77
Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease
Rip, J., de Bruijn, M. J. W., Appelman, M. K., Singh, S. P., Hendriks, R. W., & Corneth, O. B. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00095 · Cited by 77
Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
Khojah, A. M., Miller, M. L., Klein‐Gitelman, M. S., Curran, M. L., Hans, V., Pachman, L. M., & Fuleihan, R. (2019) · Pediatric Rheumatology · doi:10.1186/s12969-019-0365-y · Cited by 77
Giacomelli, R., Afeltra, A., Bartoloni, E., Berardicurti, O., Bombardieri, M., Bortoluzzi, A., Carubbi, F., Caso, F., Cervera, R., Ciccia, F., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102738 · Cited by 78
Current management of juvenile idiopathic arthritis
Wallace, C. A. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.11.008 · Cited by 77
Rituximab for the treatment of acquired antibodies to factor VIII
Sperr, W. R., Lechner, K., & Pabinger, I. (2007) · Haematologica · doi:10.3324/haematol.10553 · Cited by 77
Contemporary treatment of systemic lupus erythematosus: an update for clinicians
Amissah-Arthur, M., & Gordon, C. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310380100 · Cited by 76
Hsue, P. Y., Scherzer, R., Grünfeld, C., Imboden, J. B., Wu, Y., del Puerto, G., Nitta, E. M., Shigenaga, J. K., Heringer, A. S., Ganz, P., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001267 · Cited by 76
Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years
Aguiar, R., Araújo, C., Martins‐Coelho, G., & Isenberg, D. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.22921 · Cited by 75
Zhang, Y., Cao, R. Y., Ying, H., Du, J., Chen, S., Wang, N., & Shen, B. (2018) · Mediators of Inflammation · doi:10.1155/2018/9372436 · Cited by 75
Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients
Labrosse, R., Barmettler, S., Dérfalvi, B., Blincoe, A., Cros, G., Lacombe‐Barrios, J., Barsalou, J., Yang, N. J., AlRumayyan, N., Sinclair, J. P., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.03.041 · Cited by 75
Chapter 5 Human B Cell Subsets
Jackson, S. M., Wilson, P. C., James, J. A., & Capra, J. D. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00405-7 · Cited by 75
CD137 Promotes Proliferation and Survival of Human B Cells
Zhang, X., Voskens, C., Sallin, M. A., Maniar, A., Montes, C. L., Zhang, Y., Lin, W., Li, G., Burch, E. E., Tan, M., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901619 · Cited by 75
Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis
Toubi, E., Kessel, A., Slobodin, G., Boulman, N., Pavlotzky, E., Zisman, D., Rozenbaum, M., & Rosner, I. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062505 · Cited by 75
Strand, V., Balbir‐Gurman, A., Pavelká, K., Emery, P., Li, N., Yin, M. H., Lehane, P. B., & Agarwal, S. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel358 · Cited by 75
Self-citationMoore, T. L. (2012) · Pathy's Principles and Practice of Geriatric Medicine · doi:10.1002/9781119952930.ch94 · Cited by 75
Yang, J.-X., Wang, H., Chen, J.-Z., Li, H., Hu, J.-C., Yu, A.-A., Wen, J., Chen, S., Lai, W.-D., Wang, S., et al. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.946846 · Cited by 82
Perioperative Management of Medications Used in the Treatment of Rheumatoid Arthritis
Scanzello, C. R., Figgie, M. P., Nestor, B. J., & Goodman, S. M. (2006) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-006-9012-5 · Cited by 74
Paniagua, R. T., Chang, A., Mariano, M., Stein, E. A., Wang, Q., Lindström, T. M., Sharpe, O., Roscow, C., Ho, P. P.-K., Lee, D. M., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2940 · Cited by 72
Colitis associated with biological agents
Freeman, H. J. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i16.1871 · Cited by 74
First Latin American position paper on the pharmacological treatment of rheumatoid arthritis
(GLADAR), B. T. L. A. R. A. O. T. P.-A. L. O. A. F. R. (. A. T. G. L. D. E. D. A. R. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kei500 · Cited by 74
Nard, F. D. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i3.344 · Cited by 73
The impact of biological therapy on regulatory T cells in rheumatoid arthritis
Byng-Maddick, R., & Ehrenstein, M. R. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/keu487 · Cited by 73
NF-κB signaling in rheumatoid arthritis with focus on fibroblast-like synoviocytes
Samimi, L. N., Farhadi, E., Tahmasebi, M. N., Jamshidi, A., Vaziri, A. S., & Mahmoudi, M. (2020) · Autoimmunity Highlights · doi:10.1186/s13317-020-00135-z · Cited by 80
Autoimmune regulation of chronic pain
Lacagnina, M. J., Heijnen, C. J., Watkins, L. R., & Grace, P. M. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000905 · Cited by 76
Hamel, K. M., Cao, Y., Wang, Y., Rodeghero, R., Kobezda, T., Chen, L., & Finnegan, A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040690 · Cited by 73
Schmidt, B. J., Casey, F., Paterson, T. S., & Chan, J. R. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-221 · Cited by 72
Advances in diagnosing and managing antibody-mediated rejection
Jordan, S. C., Reinsmoen, N. L., Peng, A., Lai, C.-H., Cao, K., Villicana, R., Toyoda, M., Kahwaji, J. M., & Vo, A. A. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1386-4 · Cited by 73
Boleto, G., Kanagaratnam, L., Dramé, M., & Salmon, J. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.12.003 · Cited by 72
Crosstalk between B cells and neutrophils in rheumatoid arthritis
Karmakar, U., & Vermeren, S. (2021) · Immunology · doi:10.1111/imm.13412 · Cited by 71
Radu, A.-F., BUNGAU, S. G., Negru, P. A., Marcu, F. M., & Andronie-Cioară, F. L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113614 · Cited by 73
Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis☆
Abramson, S. B., & Yazıcı, Y. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.008 · Cited by 72
Long-term protection after immunization with protein–polysaccharide conjugate vaccines in infancy
Rohner, G. B., & Pollard, A. J. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.14 · Cited by 69
Metadata
- Authors
- Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T.
- Affiliations
- University College London (GB)
- University of Wrocław (PL)
- Roche (United Kingdom) (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-17
- Volume
- 350
- Issue
- 25
- Pages
- 2572-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118994799
- Cited by
- 2,623
- References
- 21
- Citations by year
- 2026: 65 · 2025: 69 · 2024: 76 · 2023: 62 · 2022: 61 · 2021: 85 · 2020: 87 · 2019: 85 · 2018: 103 · 2017: 112 · 2016: 96 · 2015: 103 · 2014: 129 · 2013: 133 · 2012: 133
- FWCI
- 109.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, rituximab, B-cell depletion, cyclophosphamide, methotrexate, combination therapy, adverse events, serious infections, immunoglobulin levels, treatment-resistant rheumatoid arthritis, ACR response criteria, EULAR response criteria, maintenance therapy, relapse prevention, long-term follow-up, drug efficacy
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Arthritis, Rheumatoid, B-Lymphocytes, Bacterial Infections, Cyclophosphamide, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Methotrexate, Middle Aged, Antirheumatic Agents, Antigens, CD20, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
